Dalpiciclib + Fulvestrant in Relapsed or Progressed HR+/HER2- Breast Cancer

作者
Frieda Wiley
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:43 (S15): 27-27
标识
DOI:10.1097/01.cot.0000771944.33975.d6
摘要

breast cancer: breast cancerResistance to endocrine therapy often plays a crucial role in HR+ advanced breast cancer, frequently driven by hyperactivity of cyclin D-cyclin-dependent kinase 46 (CDK4/6). These findings have prompted researchers to explore the potential benefits of treating such cancers with therapies that inhibit CDK4/6 activity. “CDK4/6 inhibitors with endocrine therapy have been shown to improve survival outcomes in pretreated patients with HR+/HER2-advanced breast cancer progressing on endocrine therapy,” said Xu Binghe, MD, at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing. In previous research, the novel CDK4/6 inhibitor dalpiciclib (SHR6390) demonstrated tolerability and preliminary antitumor activity in heavily pretreated HR+/HER2- advanced breast cancer. Binghe and his colleagues expounded the compelling research by conducting DAWNA-1, a randomized, Phase III clinical trial evaluating the effects of dalpiciclib administered with fulvestrant concomitantly in HR+/HER2- advanced breast cancer patients whose cancers had either relapsed or progressed while on previous endocrine therapy. Binghe presented data from DAWNA-1 at the ASCO 2021 Annual Meeting (Abstract 1002). Study Design Abstract 1002 DAWNA enrolled 361 women from 39 centers with HR+/HER2- metastatic or locally advanced breast cancer whose cancer had progressed either during or after receiving endocrine therapy in the adjuvant or metastatic setting. Eligible enrollees had an ECOG PS 0/1 and could not have received more than one previous chemotherapy treatment for advanced cancer. Patients were stratified based on the presence of visceral metastases as well as their menopausal status. “Characteristics were generally balanced between the two groups,” Binghe told ASCO 2021 attendees. “About 60 percent of the study patients had visceral metastases and 45 percent were pre- or peri-menopausal women. The majority of patients had received one prior line of endocrine therapy.” Researchers randomized the 361 patients 2:1 to receive dalpiciclib with fulvestrant [(n=261) dalpiciclib 150 mg orally once daily for 21 days every 4 weeks)] or placebo with fulvestrant [(n=120), (fulvestrant; 500 mg during cycle 1, day 1 and 15 then day 1 every 4 weeks)]. Patients who received dalpiciclib-fulvestrant showed significant improvements in INV-assessed PFS over a median follow-up of 10.5 months compared to the placebo-fulvestrant group (median 15.7 [95% CI 11.1-NR] vs. 7.2 [95% CI 0.31-058]; P <0.0001). The COVID-19 pandemic forced Binghe and his colleagues to adjust their study design. “The initially planned sample size for the study was 288 patients, which provides 90 percent power to detect a hazard ratio of 0.6 for the dalpiciclib group versus the placebo group, with a one-sided significance level of 0.025,” explained Binghe. “With the outbreak of COVID-19 pandemic, we amended the protocol and increased the sample size to 357 patients, based on the recommendations from the Internal Displacement Monitoring Centre.” Research Findings Investigator-assessed progression-free survival (INV-PFS) served as the primary endpoint for DAWNA-1. Secondary endpoints included independent review committee progression-free survival (IRC-PFS), objective response rate (ORR), overall survival (OS), and clinical benefit response (CBR). The median follow-up was ~10.7 months. Binghe and colleagues found that median progression-free survival (PFS) was 15.7 months in the dalpiciclib + fulvestrant arm compared with 7.2 months in the placebo group (HR=0.42, p<0.0001). Based on data collected by the planned cutoff date of November 15, 2020, nearly three-fourths of the projected number of PFS had occurred (71.4%), and investigators had conducted a preplanned interim analysis, which yielded what Binghe referred to as a “one-sided [p-value of] less than 0.008.” “The PFS results based on independent review committee assessment were consistent with the primary analysis, showing a reduction in the risk of progression or death by 55 percent in dalpiciclib group versus the placebo group.” In addition, all indicators of PFS in the subgroups favor the dalpiciclib group over the placebo group. The ORR in the dalpiciclib group versus the placebo group was 27.0 percent versus 20.0 percent. The CBR was 61.0 percent versus 45.8 percent. Similarly, tumor response favored the dalpiciclib combination therapy, as assessed by the independent review committee. Patients in the dalpiciclib arm had similar durations of exposure for both dapiciclib and fulvestrant (9.4 months vs. 9.9 months). The most common grade 3 or 4 adverse events observed were neutropenia (84.2% vs. 0%) and leukopenia (62.1% vs. 0%), and more adverse events were observed in the dalpiciclib group than the placebo group. However, Binghe noted that patients on dalpiciclib therapy who experienced the adverse events generally tolerated them well. In the dalpiciclib arm, 96 patients discontinued treatment due to disease progression (n=83), an adverse event (n=8), patient decision (n=4), or some other reason (n=1). The majority of the 77 patients who discontinued treatment in the placebo arm did so due to disease progression (n=68). Additional reasons patients did not finish the study included an adverse event (n=5), patient decision (n=1), and investigation decision (n=1). Death also precluded 1 patient from continuing the study in the placebo arm. No cause of death was given. Despite facing COVID-19-related challenges, Binghe indicated that the study's findings still yield some clinical significance overall. “This Phase III study met its primary endpoint by demonstrating that dalpiciclib plus fulvestrant significantly improved PFS versus placebo plus fulvestrant,” Xu summarized. “While overall survival data were not mature yet, the benefit of dalpiciclib beyond the initial study treatment was shown with delayed time to first subsequent chemotherapy.” Frieda Wiley is a contributing writer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CarryLJR的应助被积极纲采纳,获得10
刚刚
JamesPei的应助被小亦雪采纳,获得10
刚刚
刚刚
傲娇小懒猪完成签到,获得积分10
刚刚
刚刚
NQ完成签到,获得积分10
刚刚
1秒前
无极微光的应助被lilil采纳,获得20
1秒前
思源的应助被qearl采纳,获得10
1秒前
1秒前
章鱼烧完成签到 ,获得积分10
1秒前
拼搏菲鹰完成签到,获得积分10
1秒前
科研通AI65的应助被米米采纳,获得10
1秒前
我是谁的应助被酷炫的迎彤采纳,获得50
1秒前
需要各位资源大佬关照的小趴菜完成签到,获得积分10
2秒前
TinLi的应助被jr采纳,获得10
2秒前
2秒前
李健的小迷弟的应助被jr采纳,获得10
2秒前
高冷百事可乐完成签到,获得积分10
2秒前
缥缈襄完成签到,获得积分10
2秒前
科研通AI2S的应助被文龙采纳,获得10
2秒前
葫芦岛王可欣完成签到,获得积分10
3秒前
3秒前
MaYue完成签到,获得积分10
3秒前
3秒前
cxyyy完成签到,获得积分10
4秒前
藕饼完成签到 ,获得积分10
4秒前
haha完成签到,获得积分10
4秒前
天真芷天完成签到,获得积分10
4秒前
lian驳回了大个的应助
4秒前
情怀的应助被早安采纳,获得10
4秒前
FashionBoy的应助被实验室采纳,获得10
4秒前
bian完成签到,获得积分10
4秒前
娃哈哈完成签到,获得积分10
4秒前
风中小鸽子完成签到,获得积分10
4秒前
5秒前
简单冬亦西完成签到,获得积分10
5秒前
科研通AI65的应助被萌萌大头菜采纳,获得10
5秒前
眯眯眼的网络完成签到,获得积分10
5秒前
三月abc完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105